Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
about
Capecitabine for ER-positive versus ER-negative breast cancerClinical management of localized colon cancer with capecitabineCapecitabine in the management of colorectal cancerCapecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancerTherapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in JapanProtocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysisEffectiveness and safety of s-1-based therapy compared with 5-Fluorouracil-based therapy for advanced colorectal cancer: a meta-analysisStructures of native human thymidine phosphorylase and in complex with 5-iodouracilOral fluoropyrimidines among the new drugs for patients with metastatic breast cancerAnti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerEffects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytesFluoropyrimidine ActivityOral drugs in the treatment of metastatic colorectal cancer.Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsDevelopment of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry.Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase.Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel.Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapyA Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerMulticentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursGemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanesA comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review.Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerInferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings
P2860
Q24194664-7D451512-033B-42FA-BCA3-9EAA671DA7B6Q24611758-D141E8F2-C0C7-469E-9538-EB661ACA0246Q24633039-6FF4211B-098D-4A36-A7B2-55932A632FA7Q24633167-7129D2F2-9D4D-4DA3-941C-9B52C0BB394EQ24633384-08219930-981C-47BA-A079-130DFDE0B25BQ24658529-A4D81F46-A776-42E1-9F45-59994ECB0D66Q25257445-C3E89348-FF75-44B7-B115-B3444AD654FFQ26865057-5AAF402A-C30A-40A7-BE6D-FFC303E1529CQ27000790-31253D1F-77D3-42DE-A137-FC4B95F19C35Q27646320-08DD644C-1323-422C-8449-4D28E44ADF15Q28366029-73D8803A-23C5-4F90-8033-4046C0DD7AF4Q28534413-0837C9D7-BBF8-47CC-8E1A-7B5163ADFAF1Q28543397-3AC108DA-CC70-4B70-AC01-A83F05C9FCB2Q29883401-1F8F185F-0FA1-4039-8F8D-5B4C518FB1FAQ30251387-44FFF299-93D9-4948-9310-39E123C2784BQ30913489-EC064BBE-B90B-4584-9D89-A9EF35CD2D03Q31149825-7293F2CC-9FD8-4523-B9FF-8C77676FE73FQ31706439-C5D4EB2E-FA38-4AA7-8982-79E5542E7BD3Q33291247-04F4CA9F-1CD2-4C32-83C2-A39008E29824Q33364558-4622534A-9CFB-4FC1-A3E2-835FFA81B573Q33368148-FED45364-9AC7-45BD-B8DC-2EE4BD4A8145Q33369276-FEC4A703-395D-4EFD-AD11-C721B23365D7Q33370632-5ABBE035-3D81-495A-BDB5-D8DC0FF02218Q33376718-8CCEAF15-8E80-4291-B2D6-51AF73AC8496Q33378228-3D486045-8ABB-461A-B26E-C0E022AF4401Q33378298-1AED37D8-BAAB-40C7-8900-7FD5BE1E93CBQ33384877-8919EB6A-7FD8-4164-A832-595B3EA335C3Q33386694-C0C40606-02AD-4295-B2A8-A29AB6398A67Q33387432-9C079D9D-19E8-4319-A5D4-072DA608C245Q33393811-5E662374-8919-4651-9408-64B84B0EB97DQ33399656-257E15B9-2456-4E31-BD7B-C9E162ED7854Q33415971-58896F8A-BA74-40FB-BCF1-031DD33E7651Q33420046-1848B78B-F10A-442A-9612-0AD86D1EA30DQ33421880-DD8408B8-64D0-42D1-8EF8-5EB875196AB2Q33426722-15CE0153-F3CE-4CB0-BB55-C532EAB8FCD4Q33430813-5FEB96ED-DE66-4680-85E4-FF00927A4C3DQ33437668-F13F176B-A0AF-4975-B599-E18C937AD9E8Q33455278-619B0F40-AA61-4D71-A174-182425612B76Q33620052-9A7F1C39-EB55-48D7-9C1B-870BB046420DQ33646009-2D5BD8A4-D5B4-4AD1-A834-9EDE7E37A57E
P2860
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Design of a novel oral fluorop ...... human liver and cancer tissue.
@ast
Design of a novel oral fluorop ...... human liver and cancer tissue.
@en
Design of a novel oral fluorop ...... human liver and cancer tissue.
@nl
type
label
Design of a novel oral fluorop ...... human liver and cancer tissue.
@ast
Design of a novel oral fluorop ...... human liver and cancer tissue.
@en
Design of a novel oral fluorop ...... human liver and cancer tissue.
@nl
altLabel
Design of a novel oral fluorop ...... human liver and cancer tissue
@en
prefLabel
Design of a novel oral fluorop ...... human liver and cancer tissue.
@ast
Design of a novel oral fluorop ...... human liver and cancer tissue.
@en
Design of a novel oral fluorop ...... human liver and cancer tissue.
@nl
P2093
P3181
P1476
Design of a novel oral fluorop ...... human liver and cancer tissue.
@en
P2093
H Ishitsuka
T Ishikawa
P304
P3181
P356
10.1016/S0959-8049(98)00058-6
P407
P577
1998-07-01T00:00:00Z